Search results for: 'part covid consumer behavior study'

The Asia-Pacific next-generation diagnostics market's revenue is projected to decline by 5.0% in 2023, attributed to the reduced demand for COVID-19-related testing. Rapid expansion in non-COVID molecular diagnostics and point-of-care testing (POCT) will not be sufficient to drive the overall recovery of the region. As companies continue to focus o...

This study presents an overview of the Asia-Pacific infectious disease point-of-care testing (POCT) market with an emphasis on some of the key trends and growth opportunities that are shaping the market. The study highlights some of the emerging business models supporting the development and adoption of innovative diagnostic tests. The Asia-Pacif...

This study focuses on clinical lab services in Thailand. A detailed analysis is provided on clinical testing services at public hospital labs and private hospital labs. Specialised labs are integrated into the independent reference labs segment. Certain trends with regard to physician office labs (POLs) in retail clinics have been mentioned in the ...

Clinical laboratories are an essential part of the health industry. Approximately 80% of physicians' diagnoses is estimated to be the result of laboratory tests. The constant pressure to reduce healthcare spending is shifting healthcare application in favor of the laboratory, making it a more valuable part of the treatment plan. Vietnam CLT marke...

28 Sep 2015  |  Asia Pacific  |  Market Research

End-User Perspectives on the SEA RIS/ PACS Market

Next-generation Imaging IT Needs Will Focus on Interoperability

Infographics

×

Picture archiving communication systems (PACS) were a real game changer 3 decades ago when, in combination with radiology information systems (RIS), they enabled rapid digitalization of medical imaging data. Today, Southeast Asia again stands at the brink of transformation as RIS PACS enter their second or third generation of deployment. In an effo...

With over-4000 pharmaceutical players, China is the second largest pharmaceutical industry globally. Although highly fragmented, global pharma and biopharmaceutical players such as Novartis, Novo Nordisk, and AstraZeneca, have a significant hold capturing at least 8-10Percentage of the market. The market being highly dependent on its distributor ne...

The Philippines is a part of the Association of Southeast Asian Nations (ASEAN) community and one of the fastest growing healthcare markets in the region. With regard to healthcare, the Philippine Government has been looking at ways to achieve 100% enrolment to PhilHealth by 2020. One of the means is by mandating all Filipinos to enrol to PhilHealt...

05 Apr 2023  |  Asia Pacific  |  Market Outlook

Asia-Pacific Pharmaceutical Industry Outlook, 2023

Disruptive Technology Adoption and Outsourcing Growth is Advancing Innovation in the Pharmaceutical Industry

Infographics

×

Asia-Pacific’s pharmaceutical market is forecast to record 4.2% growth from 2022 to 2027, with China and Japan dominating the market in terms of value. Generics dominate the regional markets based on volume, directly impacting innovator molecule uptake. Nevertheless, Asia-Pacific is establishing itself as a global innovation hub, with China, Japan,...

The market for healthcare services in Malaysia is less developed, with many clinical testing services being unavailable outside of cities. Unsubstantiated disease and unconfirmed mortality diagnoses are common in the country despite universal care, significant mixed investment in the local healthcare system, and health expenditure favourable to oth...